Overview

Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein

Status:
Completed
Trial end date:
2021-06-09
Target enrollment:
Participant gender:
Summary
The overall goal of this protocol is to evaluate [18F]MK-6240 (also known as [18F]MNI-946) a tau targeted radiopharmaceutical.
Phase:
Early Phase 1
Details
Lead Sponsor:
Invicro
Molecular NeuroImaging